Selective MAO-B inhibitors: A lesson from natural products

Molecular Diversity

Volumn 18, Issue 1, 2014, Pages 219-243

  Carradori, Simone ^a   D'Ascenzio, Melissa ^a   Chimenti, Paola ^a   Secci, Daniela ^a   Bolasco, Adriana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer's disease; Depression; MAO inhibitor; Natural products; Neuroprotection; Parkinson's disease

Indexed keywords

ANIMALS; BIOLOGICAL PRODUCTS; HUMANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84894081989     PISSN: 13811991     EISSN: 1573501X     Source Type: Journal    
DOI: 10.1007/s11030-013-9490-6     Document Type: Review

References (122)

1. Blaschko H, Richter D, Schlossmann H (1937) The inactivation of adrenaline. J Physiol 90:1-17
2. Zeller EA (1938) Über den enzymatischen abbau von histamin und diaminen. 2 Mitteilung. Helv Chim Acta 21:880-890
3. Murphy DL (1978) Substrate-selective monoamine oxidases: inhibitor, tissue, species and functional differences. Biochem Pharmacol 27:1889-1893
4. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285-1297
5. Bach AW, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC (1988) cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 85:4934-4938
6. De Colibus L, Li M, Binda C, Lustig A, Edmondson DE, Mattevi A (2005) Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc Natl Acad Sci USA 102:12684-12689. doi: 10.1073/pnas.0505975102
7. Binda C, Hubálek F, Li M, Edmondson DE, Mattevi A (2004) Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane. FEBS Lett 564:225-228. doi: 10.1016/S0014-5793(04)00209-1
8. Westlund KN, Denney RM, Rose RM, Abell CW (1988) Localization of distinct monoamine oxidase a and monoamine oxidase b cell populations in human brainstem. Neuroscience 25:439-456. doi: 10.1016/0306-4522(88)90250-3
9. Bortolato M, Chen K, Shih JC (2008) Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev 60:1527-1533. doi: 10.1016/j.addr.2008.06.002
10. Davie CA (2008) A review of Parkinson's disease. Br Med Bull 86:109-127. doi: 10.1093/bmb/ldn013
11. Youdim MBH, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295-309. doi: 10.1038/nrn1883
12. Youdim MBH, Ben-Shachar D, Riederer P (1989) Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand 80:47-54
13. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J Neurochem 52:515-520. doi: 10.1111/j.1471-4159.1989. tb09150.x
14. Fowler CJ, Wiberg A, Oreland L, Marcusson J, Winblad B (1980) The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 49:1-20
15. Benedetti MS, Dostert P (1989) Monoamine oxidase, brain ageing and degenerative diseases. Biochem Pharmacol 38:555-561. doi: 10.1016/0006-2952(89) 90198-6
16. Emilsson L, Saetre P, Balciuniene J, Castensson A, Cairns N, Jazin EE (2002) Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer's disease patients. Neurosci Lett 326:56-60. doi: 10.1016/S0304-3940(02)00307-5
17. Abell CW, Kwan SW (2001) Molecular characterization of monoamine oxidases A and B. Prog Nucl Acid Res Mol Biol 65:129-156. doi: 10.1016/S0079-6603(00) 65004-3
18. Elmer LW, Bertoni JM (2008) The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy. Expert Opin Pharmacother 9:2759-2772. doi: 10.1517/14656566.9.16.2759
19. Bolasco A, Fioravanti R, Carradori S (2005) Recent development of monoamine oxidase inhibitors. Expert Opin Ther Pat 15:1763-1782. doi: 10.1517/13543776.15.12.1763
20. Secci D, Carradori S, Bolasco A, Bizzarri B, D'Ascenzio M, Maccioni E (2012) Discovery and optimization of pyrazoline derivatives as promising monoamine oxidase inhibitors. Curr Top Med Chem 12:2240-2257. doi: 10.2174/1568026611212200009
21. Secci D, Bolasco A, Chimenti P, Carradori S (2011) The state of the art of pyrazole derivatives as monoamine oxidase inhibitors and antidepressant/ anticonvulsant agents. Curr Med Chem 18:5114-5144. doi: 10.2174/ 092986711797636090
22. Bolasco A, Carradori S, Fioravanti R (2010) Focusing on new monoamine oxidase inhibitors. Expert Opin Ther Pat 20:909-939. doi: 10.1517/13543776.2010. 495716
23. Carradori S, Secci D, Bolasco A, Chimenti P, D'Ascenzio M (2012) Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential. Expert Opin Ther Pat 22:759-801. doi: 10.1517/13543776.2012.698613
24. Herraiz T, Chaparro C (2005) Human monoamine oxidase is inhibited by tobacco smoke: \beta β -carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun 326:378-386. doi: 10.1016/j.bbrc.2004.11. 033
25. Son SY, Ma J, Kondou Y, Yoshimura M, Yamashita E, Tsukihara T (2008) Structure of human monoamine oxidase A at 2.2-Å resolution: the control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci USA 105:5739-5744. doi: 10.1073/pnas.0710626105
26. Reniers J, Robert S, Frederick R, Masereel B, Vincent S, Wouters J (2011) Synthesis and evaluation of \beta β -carboline derivatives as potential monoamine oxidase inhibitors. Bioorg Med Chem 19:134-144. doi: 10.1016/j.bmc.2010.11.041
27. Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD (2002) Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 155:732-738. doi: 10.1093/aje/155.8.732
28. Chen JF, Steyn S, Staal R, Petzer JP, Xu K, Van Der Schyf CJ, Castagnoli K, Sonsalla PK, Castagnoli N Jr, Schwarzschild MA (2002) 8-(3-Chlorostyryl) caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. J Biol Chem 277:36040-36044. doi: 10.1074/jbc.M206830200
29. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K (2001) Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21:RC143
30. Petzer JP, Castagnoli N Jr, Schwarzschild MA, Chen JF, Van der Schyf CJ (2009) Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Neurotherapeutics 6:141-151. doi: 10.1016/j.nurt.2008.10.035
31. Newman DJ (2008) Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J Med Chem 51:2589-2599. doi: 10.1021/jm0704090
32. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70:461-477. doi: 10.1021/np068054v
33. Butler MS (2004) The role of natural product chemistry in drug discovery. J Nat Prod 67:2141-2153. doi: 10.1021/np040106y
34. Breinbauer R, Manger M, Scheck M, Waldmann H (2002) Natural product guided compound library development. Curr Med Chem 9:2129-2145. doi: 10.2174/0929867023368773
35. Vina D, Serra S, Lamela M, Delogu G (2012) Herbal natural products as a source of monoamine oxidase inhibitors: a review. Curr Top Med Chem 12:2131-2144. doi: 10.2174/1568026611212200003
36. Rajput MS (2010) Natural monoamine oxidase inhibitors: a review. J Pharmacy Res 3:482-485
37. Lin RD, Hou WC, Yen KY, Lee MH (2003) Inhibition of monoamine oxidase B (MAO-B) by Chinese herbal medicines. Phytomedicine 10:650-656. doi: 10.1078/0944-7113-00324
38. Clarke SED, Ramsay RR (2011) Dietary inhibitors of monoamine oxidase A. J Neural Transm 118:1031-1041. doi: 10.1007/s00702-010-0537-x
39. Yoshino S, Hara A, Sakakibara H, Kawabata K, Tokumura A, Ishisaka A, Kawai Y, Terao J (2011) Effect of quercetin and glucuronide metabolites on the monoamine oxidase-A reaction in mouse brain mitochondria. Nutrition 27:847-852. doi: 10.1016/j.nut.2010.09.002
40. Pan Y, Kong L, Xia X, Zhang W, Xia Z, Jiang F (2005) Antidepressant-like effect of icariin and its possible mechanism in mice. Pharmacol Biochem Behav 82:686-694. doi: 10.1016/j.pbb.2005.11.010
41. Lee MH, Lin RD, Shen LY, Yang LL, Yen KY, Hou WC (2001) Monoamine oxidase B and free radical scavenging activities of natural flavonoids in Melastoma candidum D. Don. J Agric Food Chem 49:5551-5555. doi: 10.1021/jf010622j
42. Chimenti F, Cottiglia F, Bonsignore L, Casu L, Casu M, Floris C, Secci D, Bolasco A, Chimenti P, Granese A, Befani O, Turini P, Alcaro S, Ortuso F, Trombetta G, Loizzo A, Guarino I (2006) Quercetin as the active principle of Hypericum hircinum exerts a selective inhibitory activity against MAO-A: extraction, biological analysis, and computational study. J Nat Prod 69:945-949. doi: 10.1021/np060015w
43. Saaby L, Rasmussen HB, Jäger AK (2009) MAO-A inhibitory activity of quercetin from Calluna vulgaris (L.) Hull. J Ethnopharmacol 121:178-181. doi: 10.1016/j.jep.2008.10.012
44. Han XH, Hong SS, Hwang JS, Lee MK, Hwang BY, Ro JS (2007) Monoamine oxidase inhibitory components from Cayratia japonica. Arch Pharm Res 30:13-17
45. Hou WC, Lin RD, Chen CT, Lee MH (2005) Monoamine oxidase B (MAO-B) inhibition by active principles from Uncaria rhynchophylla. J Ethnopharmacol 100:216-220. doi: 10.1016/j.jep.2005.03.017
46. Hwang JS, Lee SA, Hong SS, Lee KS, Lee MK, Hwang BY, Ro JS (2005) Monoamine oxidase inhibitory components from the roots of Sophora flavescens. Arch Pharm Res 28:190-194
47. Haraguchi H, Tanaka Y, Kabbash A, Fujioka T, Ishizu T, Yagi A (2004) Monoamine oxidase inhibitors from Gentiana lutea. Phytochemistry 65:2255-2260. doi: 10.1016/j.phytochem.2004.06.025
48. Bandaruk Y, Mukai R, Kawamura T, Nemoto H, Terao J (2012) Evaluation of the inhibitory effects of quercetin-related flavonoids and tea catechins on the monoamine oxidase-A reaction in mouse brain mitochondria. J Agric Food Chem 60:10270-10277. doi: 10.1021/jf303055b
49. Han XH, Hong SS, Hwang JS, Jeong SH, Hwang JH, Lee MH, Lee MK, Lee D, Ro JS, Hwang BY (2005) Monoamine oxidase inhibitory constituents from the fruits of Cudrania tricuspidata. Arch Pharmacal Res 28:1324-1327
50. Han XH, Hwang JH, Hong SS, Choe S, Lee C, Lee MS, Lee D, Lee MK, Lee MK, Hwang BY (2010) Monoamine oxidase inhibitory flavonoids from the root bark of Cudrania tricuspidata. Nat Prod Sci 16:75-79. doi: 10.1021/np070059k
51. Stafford GI, Pedersen PD, Jäger AK, Van Staden J (2007) Monoamine oxidase inhibition by southern African traditional medicinal plants. S Afr J Bot 73:384-390. doi: 10.1016/j.sajb.2007.03.001
52. Holt A, Sharman DF, Baker GB, Palcic MM (1997) A continuous spectrophotometric assay for monoamine oxidase and related enzymes in tissue homogenates. Anal Biochem 244:384-392. doi: 10.1006/abio.1996.9911
53. Olsen HT, Stafford GI, Van Staden J, Christensen SB, Jäger AK (2008) Isolation of the MAO-inhibitor naringenin from Mentha aquatica L. J Ethnopharmacol 117:500-502. doi: 10.1016/j.jep.2008.02.015
54. Zhu W, Ma S, Qu R, Kang D, Liu Y (2006) Antidepressant effect of baicalin extracted from the root of Scutellaria baicalensis in mice and rats. J Pharm Biol 44:503-510. doi: 10.1080/13880200600878684
55. Singh R, Navneet C, Singh VK (2012) In-silico study of herbal compounds (bacailin, curcumin and dronabinol) as novel MAO inhibitors for Parkinson's disease treatment. Int J Life Sci Pharma Res 2:L81-L98
56. Gao L, Fang JS, Bai XY, Zhou D, Wang YT, Liu AL, Du GH (2013) In silico target fishing for the potential targets and molecular mechanisms of baicalein as an anti-parkinsonian agent: discovery of the protective effects on NMDA receptor-mediated neurotoxicity. Chem Biol Drug Des 81:675-687. doi: 10.1111/cbdd.12127
57. Urbain A, Marston A, Grilo LS, Bravo J, Purev O, Purevsuren B, Batsuren D, Reist M, Carrupt PA, Hostettmann K (2008) Xanthones from Gentianella amarella ssp. acuta with acetylcholinesterase and monoamine oxidase inhibitory activities. J Nat Prod 71:895-897. doi: 10.1021/np070690l
58. Dimitrov M, Nikolova I, Benbasat N, Kitanov G, Danchev N (2011) Acute toxicity, antidepressive and MAO inhibitory activity of mangiferin isolated from Hypericum Aucheri. Biotechnol Biotechnol Equip 25:2668-2671. doi: 10.5504/bbeq2011.0099
59. Fowler CJ, Tipton KF, MacKay AV, Youdim MB (1982) Human platelet monoamine oxidase - a useful enzyme in the study of psychiatric disorders. Neuroscience 7:1577-1594. doi: 10.1016/0306-4522(82)90016-1
60. Bhattacharya SK, Sanyal AK, Ghosal S (1972) Monoamine oxidase-inhibiting activity of mangiferin isolated from Canscora decussata. Naturwissenschaften 59:651
61. Dreiseitel A, Korte G, Schreier P, Oehme A, Locher S, Domani M, Hajak G, Sand PG (2009) Berry anthocyanins and their aglycons inhibit monoamine oxidases A and B. Pharmacol Res 59:306-311. doi: 10.1016/j.phrs.2009.01.014
62. Xu Y, Li S, Chen R, Li G, Barish PA, You W, Chen L, Lin M, Ku B, Pan J, Ogle WO (2010) Antidepressant-like effect of low molecular proanthocyanidin in mice: involvement of monoaminergic system. Pharmacol Biochem Behav 94:447-453. doi: 10.1016/j.pbb.2009.10.007
63. Moreira ELG, Rial D, Aguiar AS Jr, Figueiredo CP, Siqueira JM, Dalbo S, Horst H, Oliveira J, Mancini G, dos Santos TS, Villarinho JG, Pinheiro FV, Marino-Neto J, Ferreira J, Bem AF, Latini A, Pizzolatti MG, Ribeiro-do-Valle RM, Prediger RDS (2010) Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine rat model of Parkinson's disease. J Neural Transm 117:1337-1351. doi: 10.1007/s00702-010-0464-x
64. Matsumoto T, Suzuki O, Furuta T, Asai M, Kurokawa Y, Nimura Y, Katsumata Y, Takahashi I (1985) A sensitive fluorometric assay for serum monoamine oxidase with kynuramine as substrate. Clin Biochem 18:126-129. doi: 10.1016/S0009-9120(85)80094-1
65. Lin SM, Wang SW, Ho SC, Tang YL (2010) Protective effect of green tea (- -)-epigallocatechin-3-gallate against the monoamine oxidase B enzyme activity increase in adult rat brains. Nutrition 26:1195-1200. doi: 10.1016/j.nut.2009. 11.022
66. Reznichenko L, Kalfon L, Amit T, Youdim MBH, Mandel SA (2010) Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced Parkinsonism. Neurodegener Dis 7:219-231. doi: 10.1159/000265946
67. Zhang XL, Jiang B, Li ZB, Hao S, An LJ (2007) Catalpol ameliorates cognition deficits and attenuates oxidative damage in the brain of senescent mice induced by d-galactose. Pharmacol Biochem Behav 88:64-72. doi: 10.1016/j.pbb.2007.07.004
68. Bi J, Wang XB, Chen L, Hao S, An LJ, Jiang B, Guo L (2008) Catalpol protects mesencephalic neurons against MPTP induced neurotoxicity via attenuation of mitochondrial dysfunction and MAO-B activity. Toxicol Vitro 22:1883-1889. doi: 10.1016/j.tiv.2008.09.007
69. Kim JH, Kim GH, Hwang KH (2012) Monoamine oxidase and dopamine \beta β -hydroxylase inhibitors from the fruits of Gardenia jasminoides. Biomol Ther 20:214-219. doi: 10.4062/biomolther.2012.20.2.214
70. Han YN, Choo Y, Lee YC, Moon YI, Kim SD, Choi JW (2001) Monoamine oxidase B inhibitors from the fruits of Opuntia ficus-indica var. saboten. Arch Pharm Res 24:51-54
71. Xu Y, Ku BS, Yao HY, Lin YH, Ma X, Zhang YH, Li XJ (2005) The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol 518:40-46. doi: 10.1016/j.ejphar.2005.06.002
72. Kulkarni SK, Bhutani MK, Bishnoi M (2008) Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berlin) 201:435-442. doi: 10.1007/s00213-008-1300-y
73. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS (1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64:353-356. doi: 10.1055/s-2006-957450
74. Rajeswari A, Sabesan M (2008) Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice. Inflammopharmacology 16:96-99. doi: 10.1007/s10787-007-1614-0
75. Morinan A, Garratt HM (1985) An improved fluorimetric assay for brain monoamine oxidase. J Pharmacol Methods 13:213-223
76. Zbarsky V, Datla KP, Parkar S, Rai DK, Aruoma OI, Dexter DT (2005) Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic Res 39:1119-1125. doi: 10.1080/10715760500233113
77. Ucar G, Tas C, Tümer A (2005) Monoamine oxidase inhibitory activities of the scorpion Mesobuthus gibbosus (Buthidae) venom peptides. Toxicon 45:43-52. doi: 10.1016/j.toxicon.2004.09.009
78. Saidemberg DM, Ferreira MAB, Takahashi TN, Gomes PC, Cesar-Tognoli LMM, Da Silva-Filho LC, Tormena CF, Da Silva GVJ, Palma MS (2009) Monoamine oxidase inhibitory activities of indolylalkaloid toxins from the venom of the colonial spider Parawixia bistriata: functional characterization of PwTX-I. Toxicon 54:717-724. doi: 10.1016/j.toxicon.2009.05.027
79. Buckholtz NS (1980) Brain serotonin and 5-hydroxyindoleacetic acid concentrations and serotonin synthesis following tetrahydro- \beta β -carboline administration in mice. Naunyn Schmiedebergs Arch Pharmacol 314:215-221
80. Cesar LMM, Tormena CF, Marques MR, da Silva GVJ, Mendes MA, Rittner R, Palma MS (2005) Structure determination of hydroxytrypargine: a new tetrahydro- \beta β -carboline toxin from the venom of the spider Parawixia bistriata. Helv Chim Acta 88:796-801. doi: 10.1002/hlca.200590056
81. Rommelspacher H, Meier-Henco M, Smolka M, Kloft C (2002) The levels of norharman are high enough after smoking to affect monoamine oxidase B in platelets. Eur J Pharmacol 441:115-125. doi: 10.1016/S0014-2999(02)01452-8
82. Cesar LMM, Mendes MA, Tormena CF, Marques MR, De Souza BM, Saidemberg DM, Bittencourt JC, Palma MS (2005) Isolation and chemical characterization of PwTx-II: a novel alkaloid toxin from the venom of the spider Parawixia bistriata (Araneidae, Araneae). Toxicon 46:786-796. doi: 10.1016/j.toxicon.2005.08.005
83. Han XH, Hong SS, Lee D, Lee JJ, Lee MS, Moon DC, Han K, Oh KW, Lee MK, Ro JS, Hwang BY (2007) Quinolone alkaloids from Evodiae fructus and their inhibitory effects on monoamine oxidase. Arch Pharm Res 30:397-401
84. Lee MK, Hwang BY, Lee SA, Oh GJ, Choi WH, Hong SS, Lee KS, Ro JS (2003) 1-Methyl-2-undecyl-4(1H)-quinolone as an irreversible and selective inhibitor of type B monoamine oxidase. Chem Pharm Bull 51:409-411. doi: 10.1248/cpb.51.409
85. Krajl M (1965) A rapid microfluorimetric determination of monoamine oxidase. Biochem Pharmacol 14:1684-1685. doi: 10.1016/0006-2952(65)90025-0
86. Lee SA, Hong SS, Han XH, Hwang JS, Oh GJ, Lee KS, Lee MK, Hwang BY, Ro JS (2005) Piperine from the fruits of Piper longum with inhibitory effect on monoamine oxidase and antidepressant-like activity. Chem Pharm Bull 53:832-835. doi: 10.1007/s12272-001-1212-7
87. Kong LD, Cheng CHK, Tan RX (2004) Inhibition of MAO A and B by some plant-derived alkaloids, phenols and anthraquinones. J Ethnopharmacol 91:351-355. doi: 10.1016/j.jep.2004.01.013
88. Lee SA, Hwang JS, Han XH, Lee C, Lee MH, Choe SG, Hong SS, Lee D, Lee MK, Hwang BY (2008) Methylpiperate derivatives from Piper longum and their inhibition of monoamine oxidase. Arch Pharm Res 31:679-683. doi: 10.1007/s12272-001-1212-7
89. Ji HF, Shen L (2011) Berberine: a potential multipotent natural product to combat Alzheimer's disease. Molecules 16:6732-6740. doi: 10.3390/ molecules16086732
90. Peng WH, Lo KL, Lee YH, Hung TH, Lin YC (2007) Berberine produces antidepressant-like effects in the forced swim test and in the tail suspension test in mice. Life Sci 81:933-938. doi: 10.1016/j.lfs.2007.08.003
91. Kulkarni SK, Dhir A (2008) On the mechanism of antidepressant-like action of berberine chloride. Eur J Pharmacol 589:163-172. doi: 10.1016/j.ejphar.2008. 05.043
92. Castillo J, Hung J, Rodriguez M, Bastidas E, Laboren I, Jaimes A (2005) LED fluorescence spectroscopy for direct determination of monoamine oxidase B inactivation. Anal Biochem 343:293-298. doi: 10.1016/j.ab.2005.05.027
93. Lee SS, Kai M, Lee MK (1999) Effects of natural isoquinoline alkaloids on monoamine oxidase activity in mouse brain: inhibition by berberine and palmatine. Med Sci Res 27:749-751
94. Kong LD, Cheng CH, Tan RX (2001) Monoamine oxidase inhibitors from rhizoma of Coptis chinensis. Planta Med 67:74-76. doi: 10.1055/s-2001-10874
95. Lambert DM, Fowler CJ (2005) The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 48:5059-5087. doi: 10.1021/jm058183t
96. Fišar Z (2012) Cannabinoids and monoamine neurotransmission with focus on monoamine oxidase. Prog Neuropsychopharmacol Biol Psychiatry 38:68-77. doi: 10.1016/j.pnpbp.2011.12.010
97. Hill MN, Hillard CJ, Bambico FR, Patel S, Gorzalka BB, Gobbi G (2009) The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol Sci 30:484-493. doi: 10.1016/j.tips.2009.06.006
98. Laviolette SR, Grace AA (2006) The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci 63:1597-1613. doi: 10.1007/s00018-006-6027-5
99. Hill MN, Ho WSV, Hillard CJ, Gorzalka BB (2008) Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents. J Neural Transm 115:1673-1679. doi: 10.1007/s00702-008-0131-7
100. Faraj BA, Davis DC, Camp VM, Mooney AJ 3rd, Holloway T, Barika G (1994) Platelet monoamine oxidase activity in alcoholics, alcoholics with drug dependence, and cocaine addicts. Alcohol Clin Exp Res 18:1114-1120. doi: 10.1111/j.1530-0277.1994.tb00090.x
101. Fišar Z (2010) Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs Arch Pharmacol 381:563-572. doi: 10.1007/s00210-010-0517-6
102. Egashira T, Takayama F, Yamanaka Y (1999) The inhibition of monoamine oxidase activity by various antidepressants: differences found in various mammalian species. Jpn J Pharmacol 81:115-121. doi: 10.1254/jjp.81.115
103. Singh GK, Garabadu D, Muruganandam AV, Joshi VK, Krishnamurthy S (2009) Antidepressant activity of Asparagus racemosus in rodent models. Pharmacol Biochem Behav 91:283-290. doi: 10.1016/j.pbb.2008.07.010
104. Meena J, Ojha R, Muruganandam AV, Krishnamurthy S (2011) Asparagus racemosus competitively inhibits in vitro the acetylcholine and monoamine metabolizing enzymes. Neurosci Lett 503:6-9. doi: 10.1016/j.neulet.2011.07.051
105. Naoi M, Nagatsu T (1986) Inhibition of monoamine oxidase by 3,4-dihydroxyphenylserine. J Neurochem 47:604-607. doi: 10.1111/j.1471-4159. 1986.tb04542.x
106. Mohanasundari M, Sabesan M (2007) Modulating effect of Hypericum perforatum extract on astrocytes in MPTP induced Parkinson's disease in mice. Eur Rev Med Pharmacol Sci 11:17-20
107. Van Diermen D, Marston A, Bravo J, Reist M, Carrupt PA, Hostettmann K (2009) Monoamine oxidase inhibition by Rhodiola rosea L. roots. J Ethnopharmacol 122:397-401. doi: 10.1016/j.jep.2009.01.007
108. Mazzio EA, Harris N, Soliman KF (1998) Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells. Planta Med 64:603-606. doi: 10.1055/s-2006-957530
109. Chen XG, Jia YG, Wang BX (1992) Inhibitory effects of the extract of pilose antler on monoamine oxidase in aged mice. China J Chin Materia Med 2:107-110
110. Yang XW (1995) HPLC analysis and inhibitory effect of base components in pilose antler of sika deer and red deer on monoamine oxidase activity. Chin Tradit Herbal Drugs 26:17-19
111. Zhou R, Wang J, Li S, Liu Y (2009) Supercritical fluid extraction of monoamine oxidase inhibitor from antler velvet. Sep Purif Technol 65:275-281. doi: 10.1016/j.seppur.2008.10.036
112. Wang BX, Chen XG (1989) Inhibitory effect of hypoxanthine on monoamine oxidase activity. Acta Pharm Sinica 24:573-577
113. Hwang KH, Choi K, Park KW (2012) Composition comprising the extract of Loranthus yadoriki sieb having monoamine oxidase-inhibiting activity. WO 2012/081831
114. Hwang KH, Song I (2003) The inhibitory activity on monoamine oxidase of the fruit of Morus alba. Kor J Pharmacogn 34:185-189
115. McEwen CM Jr, Cohen JD (1963) An amine oxidase in normal human serum. J Lab Clin Med 62:766-776
116. Secci D, Carradori S, Bolasco A, Chimenti P, Yáñez M, Ortuso F, Alcaro S (2011) Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives. Eur J Med Chem 46:4846-4852. doi: 10.1016/j.ejmech.2011.07.017
117. Chimenti F, Bolasco A, Secci D, Bizzarri B, Chimenti P, Granese A, Carradori S (2010) Synthesis and characterization of new 3-acyl-7-hydroxy-6,8- substituted-coumarin and 3-acyl-7-benzyloxy-6,8-substituted-coumarin derivatives. J Heterocycl Chem 47:729-733. doi: 10.1002/jhet.362
118. Chimenti F, Carradori S, Secci D, Bolasco A, Chimenti P, Granese A, Bizzarri B (2009) Synthesis and biological evaluation of novel conjugated coumarin-thiazole systems. J Heterocycl Chem 46:575-578. doi: 10.1002/jhet.110
119. Chimenti F, Secci D, Bolasco A, Chimenti P, Bizzarri B, Granese A, Carradori S, Yáñez M, Orallo F, Ortuso F, Alcaro S (2009) Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem 52:1935-1942. doi: 10.1021/jm801496u
120. Chimenti F, Secci D, Bolasco A, Chimenti P, Granese A, Carradori S, Befani O, Turini P, Alcaro S, Ortuso F (2006) Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of N, N^{\prime } N, N ′ -bis[2-oxo-2 H H -benzopyran]-3-carboxamides. Bioorg Med Chem Lett 16:4135-4140. doi: 10.1016/j.bmcl.2006.04.026
121. Petzer A, Pienaar A, Petzer JP (2013) The interactions of caffeine with monoamine oxidase. Life Sci 93:283-287. doi: 10.1016/j.lfs.2013.06.020
122. Van der Walt MM, Terre'Blanche G, Petzer A, Lourens ACU, Petzer JP (2013) The adenosine \text{ A }-{{\rm 2A}} A 2 A antagonistic properties of selected C8-substituted xanthines. Bioorg Chem 49:49-58. doi: 10.1016/j.bioorg.2013.06. 006